Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 32.79
(2.63%)
USD 32.79
(2.63%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -366.28 Million USD | -35.66% |
| 2022 | -270 Million USD | -831.03% |
| 2021 | -29 Million USD | 94.05% |
| 2020 | -487 Million USD | -265.65% |
| 2019 | 294 Million USD | 7.4% |
| 2018 | 273.74 Million USD | 4685.28% |
| 2017 | -5.97 Million USD | 93.1% |
| 2016 | -86.55 Million USD | 1.95% |
| 2015 | -88.27 Million USD | -126.45% |
| 2014 | -38.98 Million USD | 35.72% |
| 2013 | -60.64 Million USD | 7.38% |
| 2012 | -65.47 Million USD | 22.79% |
| 2011 | -84.8 Million USD | -38.45% |
| 2010 | -61.25 Million USD | -139.5% |
| 2009 | 155.06 Million USD | 1396.21% |
| 2008 | -11.96 Million USD | -8.81% |
| 2007 | -10.99 Million USD | 76.05% |
| 2006 | -45.9 Million USD | 36.6% |
| 2005 | -72.4 Million USD | 49.19% |
| 2004 | -142.5 Million USD | -50.01% |
| 2003 | -94.99 Million USD | -31.5% |
| 2002 | -72.24 Million USD | 2.15% |
| 2001 | -73.83 Million USD | -38.04% |
| 2000 | -53.48 Million USD | 9.65% |
| 1999 | -59.2 Million USD | -37.67% |
| 1998 | -43 Million USD | -38.26% |
| 1997 | -31.1 Million USD | -17.36% |
| 1996 | -26.5 Million USD | -11.81% |
| 1995 | -23.7 Million USD | -30.22% |
| 1994 | -18.2 Million USD | 4.71% |
| 1993 | -19.1 Million USD | 2.05% |
| 1992 | -19.5 Million USD | -124.14% |
| 1991 | -8.7 Million USD | -93.33% |
| 1990 | -4.5 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -142.8 Million USD | -1441.65% |
| 2024 Q2 | -66.26 Million USD | 53.6% |
| 2023 Q3 | -147 Million USD | -72.94% |
| 2023 Q4 | -9.26 Million USD | 93.7% |
| 2023 FY | -366.28 Million USD | -35.66% |
| 2023 Q1 | -124 Million USD | -138.46% |
| 2023 Q2 | -85 Million USD | 31.45% |
| 2022 Q1 | -65.16 Million USD | -128.96% |
| 2022 Q2 | -105.13 Million USD | -61.34% |
| 2022 Q3 | -46.99 Million USD | 55.3% |
| 2022 Q4 | -52 Million USD | -10.66% |
| 2022 FY | -270 Million USD | -831.03% |
| 2021 FY | -29 Million USD | 94.05% |
| 2021 Q1 | -89.86 Million USD | 73.57% |
| 2021 Q2 | -80.87 Million USD | 10.01% |
| 2021 Q4 | 225 Million USD | 372.84% |
| 2021 Q3 | -82.46 Million USD | -1.97% |
| 2020 Q1 | -48.22 Million USD | -126.21% |
| 2020 FY | -487 Million USD | -265.65% |
| 2020 Q2 | -31.84 Million USD | 33.97% |
| 2020 Q3 | -30.94 Million USD | 2.83% |
| 2020 Q4 | -340 Million USD | -998.76% |
| 2019 FY | 294 Million USD | 7.4% |
| 2019 Q1 | 84.44 Million USD | -73.62% |
| 2019 Q3 | 26.16 Million USD | 2716.3% |
| 2019 Q2 | -1 Million USD | -101.18% |
| 2019 Q4 | 184 Million USD | 603.28% |
| 2018 Q2 | -40.35 Million USD | -2742.11% |
| 2018 Q4 | 320.07 Million USD | 7120.79% |
| 2018 FY | 273.74 Million USD | 4685.28% |
| 2018 Q3 | -4.55 Million USD | 88.7% |
| 2018 Q1 | -1.42 Million USD | -151.75% |
| 2017 FY | -5.97 Million USD | 93.1% |
| 2017 Q1 | 3.46 Million USD | -86.59% |
| 2017 Q4 | 2.74 Million USD | 381.15% |
| 2017 Q3 | -976 Thousand USD | 91.29% |
| 2017 Q2 | -11.2 Million USD | -423.13% |
| 2016 Q4 | 25.86 Million USD | 251.86% |
| 2016 Q2 | -56.85 Million USD | 9.63% |
| 2016 Q3 | 7.35 Million USD | 112.93% |
| 2016 FY | -86.55 Million USD | 1.95% |
| 2016 Q1 | -62.91 Million USD | 11.92% |
| 2015 Q4 | -71.43 Million USD | -99.67% |
| 2015 Q1 | -16.71 Million USD | -153.83% |
| 2015 Q2 | 35.64 Million USD | 313.24% |
| 2015 Q3 | -35.77 Million USD | -200.36% |
| 2015 FY | -88.27 Million USD | -126.45% |
| 2014 Q2 | -12.08 Million USD | 61.38% |
| 2014 FY | -38.98 Million USD | 35.72% |
| 2014 Q4 | 31.05 Million USD | 216.41% |
| 2014 Q1 | -31.28 Million USD | -28.85% |
| 2014 Q3 | -26.67 Million USD | -120.81% |
| 2013 Q3 | -24.57 Million USD | -142.64% |
| 2013 FY | -60.64 Million USD | 7.38% |
| 2013 Q4 | -24.27 Million USD | 1.2% |
| 2013 Q2 | -10.12 Million USD | -505.62% |
| 2013 Q1 | -1.67 Million USD | 36.59% |
| 2012 Q3 | -37.63 Million USD | -3018.39% |
| 2012 Q1 | -23.99 Million USD | -19.76% |
| 2012 Q4 | -2.63 Million USD | 92.99% |
| 2012 FY | -65.47 Million USD | 22.79% |
| 2012 Q2 | -1.2 Million USD | 94.97% |
| 2011 Q4 | -20.03 Million USD | 25.47% |
| 2011 FY | -84.8 Million USD | -38.45% |
| 2011 Q1 | -19.99 Million USD | -42.96% |
| 2011 Q2 | -17.88 Million USD | 10.53% |
| 2011 Q3 | -26.88 Million USD | -50.27% |
| 2010 FY | -61.25 Million USD | -139.5% |
| 2010 Q4 | -13.98 Million USD | -12.3% |
| 2010 Q2 | -25.15 Million USD | -160.45% |
| 2010 Q1 | -9.65 Million USD | -38.8% |
| 2010 Q3 | -12.45 Million USD | 50.49% |
| 2009 FY | 155.06 Million USD | 1396.21% |
| 2009 Q3 | -6.92 Million USD | -139.09% |
| 2009 Q2 | -2.89 Million USD | -101.69% |
| 2009 Q4 | -6.95 Million USD | -0.49% |
| 2009 Q1 | 171.84 Million USD | 2084.79% |
| 2008 Q2 | -2.2 Million USD | 48.47% |
| 2008 Q4 | -8.65 Million USD | -371.58% |
| 2008 FY | -11.96 Million USD | -8.81% |
| 2008 Q1 | -4.28 Million USD | 38.41% |
| 2008 Q3 | 3.18 Million USD | 244.38% |
| 2007 Q3 | 20 Million USD | 281.49% |
| 2007 FY | -10.99 Million USD | 76.05% |
| 2007 Q1 | -13.02 Million USD | 7.96% |
| 2007 Q2 | -11.02 Million USD | 15.33% |
| 2007 Q4 | -6.95 Million USD | -134.77% |
| 2006 FY | -45.9 Million USD | 36.6% |
| 2006 Q4 | -14.14 Million USD | -16.86% |
| 2006 Q3 | -12.1 Million USD | -457.32% |
| 2006 Q2 | -2.17 Million USD | 87.57% |
| 2006 Q1 | -17.48 Million USD | -120.9% |
| 2005 Q3 | -15.17 Million USD | 22.82% |
| 2005 Q4 | -7.91 Million USD | 47.84% |
| 2005 Q2 | -19.65 Million USD | 33.71% |
| 2005 FY | -72.4 Million USD | 49.19% |
| 2005 Q1 | -29.65 Million USD | 48.46% |
| 2004 FY | -142.5 Million USD | -50.01% |
| 2004 Q1 | -26.3 Million USD | -3.67% |
| 2004 Q2 | -25.94 Million USD | 1.36% |
| 2004 Q3 | -32.7 Million USD | -26.05% |
| 2004 Q4 | -57.54 Million USD | -75.92% |
| 2003 Q4 | -25.37 Million USD | -14.29% |
| 2003 Q2 | -23.09 Million USD | 5.03% |
| 2003 FY | -94.99 Million USD | -31.5% |
| 2003 Q1 | -24.32 Million USD | -53.65% |
| 2003 Q3 | -22.2 Million USD | 3.87% |
| 2002 Q1 | -17.97 Million USD | -15.02% |
| 2002 Q4 | -15.82 Million USD | 9.94% |
| 2002 Q3 | -17.57 Million USD | 15.76% |
| 2002 Q2 | -20.86 Million USD | -16.1% |
| 2002 FY | -72.24 Million USD | 2.15% |
| 2001 FY | -73.83 Million USD | -38.04% |
| 2001 Q1 | -22.84 Million USD | -47.91% |
| 2001 Q4 | -15.62 Million USD | -26.86% |
| 2001 Q3 | -12.31 Million USD | 46.55% |
| 2001 Q2 | -23.04 Million USD | -0.86% |
| 2000 Q4 | -15.44 Million USD | -185.58% |
| 2000 Q1 | -18.32 Million USD | -4.13% |
| 2000 Q3 | -5.4 Million USD | 62.18% |
| 2000 Q2 | -14.3 Million USD | 21.96% |
| 2000 FY | -53.48 Million USD | 9.65% |
| 1999 Q3 | -12.4 Million USD | 24.85% |
| 1999 FY | -59.2 Million USD | -37.67% |
| 1999 Q4 | -17.6 Million USD | -41.94% |
| 1999 Q1 | -12.6 Million USD | 24.55% |
| 1999 Q2 | -16.5 Million USD | -30.95% |
| 1998 Q3 | -1 Million USD | 92.75% |
| 1998 Q4 | -16.7 Million USD | -1570.0% |
| 1998 Q2 | -13.8 Million USD | -20.0% |
| 1998 Q1 | -11.5 Million USD | -5.5% |
| 1998 FY | -43 Million USD | -38.26% |
| 1997 FY | -31.1 Million USD | -17.36% |
| 1997 Q2 | -9.4 Million USD | -9.3% |
| 1997 Q3 | -2.2 Million USD | 76.6% |
| 1997 Q1 | -8.6 Million USD | -6.17% |
| 1997 Q4 | -10.9 Million USD | -395.45% |
| 1996 Q4 | -8.1 Million USD | -35.0% |
| 1996 Q1 | -5.1 Million USD | 0.0% |
| 1996 FY | -26.5 Million USD | -11.81% |
| 1996 Q3 | -6 Million USD | 17.81% |
| 1996 Q2 | -7.3 Million USD | -43.14% |
| 1995 Q3 | -6.9 Million USD | -16.95% |
| 1995 Q4 | -5.1 Million USD | 26.09% |
| 1995 FY | -23.7 Million USD | -30.22% |
| 1995 Q2 | -5.9 Million USD | 0.0% |
| 1995 Q1 | -5.9 Million USD | 1.67% |
| 1994 Q2 | -5.1 Million USD | -200.0% |
| 1994 Q3 | -5.4 Million USD | -5.88% |
| 1994 Q4 | -6 Million USD | -11.11% |
| 1994 FY | -18.2 Million USD | 4.71% |
| 1994 Q1 | -1.7 Million USD | 63.04% |
| 1993 Q2 | -4.8 Million USD | 5.88% |
| 1993 Q4 | -4.6 Million USD | 0.0% |
| 1993 FY | -19.1 Million USD | 2.05% |
| 1993 Q1 | -5.1 Million USD | 3.77% |
| 1993 Q3 | -4.6 Million USD | 4.17% |
| 1992 FY | -19.5 Million USD | -124.14% |
| 1992 Q2 | -4.3 Million USD | 14.0% |
| 1992 Q1 | -5 Million USD | -56.25% |
| 1992 Q3 | -4.9 Million USD | -13.95% |
| 1992 Q4 | -5.3 Million USD | -8.16% |
| 1991 Q2 | -2 Million USD | -81.82% |
| 1991 Q3 | -2.4 Million USD | -20.0% |
| 1991 Q4 | -3.2 Million USD | -33.33% |
| 1991 FY | -8.7 Million USD | -93.33% |
| 1991 Q1 | -1.1 Million USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 FY | -4.5 Million USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | -18.74% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -575.954% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -313.971% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | -4.033% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -32.652% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -209.068% |
| Imunon, Inc. | -19.51 Million USD | -1776.948% |
| Dynavax Technologies Corporation | -6.38 Million USD | -5633.072% |
| Editas Medicine, Inc. | -153.21 Million USD | -139.06% |
| FibroGen, Inc. | -284.23 Million USD | -28.869% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 17.51% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -767.997% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 246.69% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 31.66% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 27933.283% |
| Verastem, Inc. | -87.36 Million USD | -319.25% |
| Zoetis Inc. | 2.34 Billion USD | 115.627% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 110.12% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -42.064% |
| Homology Medicines, Inc. | -53.74 Million USD | -581.551% |
| Nektar Therapeutics | -276.05 Million USD | -32.685% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -326.435% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -818.931% |
| Perrigo Company plc | -12.7 Million USD | -2784.142% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -75.049% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 95.759% |
| Illumina, Inc. | -1.16 Billion USD | 68.451% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 106.11% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 126.972% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -231.304% |
| Waters Corporation | 642.23 Million USD | 157.033% |
| Biogen Inc. | 1.16 Billion USD | 131.546% |
| Evolus, Inc. | -61.68 Million USD | -493.801% |
| Adicet Bio, Inc. | -142.65 Million USD | -156.758% |
| bluebird bio, Inc. | -211.91 Million USD | -72.847% |
| Geron Corporation | -184.12 Million USD | -98.931% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 16.799% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -141.639% |
| Myriad Genetics, Inc. | -112 Million USD | -227.041% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 23.879% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 146.437% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -721.208% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 318.489% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 109.265% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 129.539% |
| OPKO Health, Inc. | -188.86 Million USD | -93.943% |
| Exelixis, Inc. | 207.76 Million USD | 276.298% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 445.097% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -671.047% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -53.105% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 230.076% |
| Blueprint Medicines Corporation | -506.98 Million USD | 27.752% |
| Insmed Incorporated | -749.56 Million USD | 51.134% |
| TG Therapeutics, Inc. | 12.67 Million USD | 2990.515% |
| Incyte Corporation | 597.59 Million USD | 161.293% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 51.836% |